Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-20T22:01:18.536Z Has data issue: false hasContentIssue false

Chapter 7 - Movement disorders in HIV- and AIDS-related central nervous system infections

from Section II - Movement disorders in systemic disease

Published online by Cambridge University Press:  05 April 2014

By
Sarah M. Kranick  and
Avindra Nath
Edited by
Werner Poewe  and
Joseph Jankovic
Sarah M. Kranick
Affiliation:
Section of Infections of the Nervous System, National Institute of Neurological Diseases & Stroke, National Institutes of Health, Bethesda, MD, USA
Avindra Nath
Affiliation:
Section of Infections of the Nervous System, National Institute of Neurological Diseases & Stroke, National Institutes of Health, Bethesda, MD, USA
Werner Poewe
Affiliation:
Medical University Innsbruck
Joseph Jankovic
Affiliation:
Baylor College of Medicine, Texas
Get access

Summary

Introduction

There are a number of important infectious etiologies that must be considered in patients presenting with movement disorders. Abnormal movements have been recognized as the presenting sign of HIV infection since the 1980s (Nath et al. 1987). While the incidence in the developed world of certain classic movement disorders due to infections, such as Sydenham’s disease, has waned with greater antimicrobial availability, physicians continue to see a wide spectrum of infectious etiologies due to patients travelling long distances, as well as increased use of immunomodulatory agents and iatrogenic immune suppression. The recognition of infectious agents in the differential diagnosis of movement disorders can be of great clinical significance when treatment for the infection is available, such as in Whipple’s disease, which has been reported in association with AIDS (Jankovic 1986); in other cases, such as prion disease, in which treatment is not available, identification of the infectious etiology is important for diagnosis, prognosis, and epidemiological control to prevent potential spread of the infection. Recognition of infectious agents as the etiology of movement disorders may also assist with localization of the lesion (see Figure 7.1). In the case of HIV infection, which is to some extent treatable as a chronic infection, neurologists must recognize abnormal movements that may be a manifestation of the infection with HIV itself, as well as those movements attributable to opportunistic infections, and those that occur as complications of combined antiretroviral therapy (cART) or symptomatic treatment. With HIV-infected patients achieving much greater length of survival, there will likely be more cases of neurodegenerative disorders such as idiopathic Parkinson’s disease (PD), and thus issues related to management of PD in patients with HIV infection will also become increasingly salient.

Type
Chapter
Information
Movement Disorders in Neurologic and Systemic Disease , pp. 89 - 98
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., et al. (2007). “Updated research nosology for HIV-associated neurocognitive disorders,” Neurology 69(18): 1789–99.CrossRefGoogle ScholarPubMed
Arendt, G., Hefter, H., Hilperath, F., von Giesen, H. J., Strohmeyer, G., and Freund, H. J. (1994). “Motor analysis predicts progression in HIV-associated brain disease,” J. Neurol. Sci. 123(1–2): 180–5.CrossRefGoogle ScholarPubMed
Berger, J., Moskowitz, L., and Fischl, M. (1984). “The neurologic complications of AIDS: frequently the initial manifestation,” Neurology 34(Suppl. 1): 134–5.Google Scholar
Berger, J. R., Kumar, M., Kumar, A., Fernandez, J. B., and Levin, B. (1994). “Cerebrospinal fluid dopamine in HIV-1 infection,” AIDS 8 (1):67–71.CrossRefGoogle ScholarPubMed
Bouffard, J. P., Mena, H., Ripple, M., and Troncoso, J. (2003). “Mesencephalic cryptococcal abscesses presenting with parkinsonism as an initial manifestation of AIDS,” Mov. Disord. 18(11): 1354–7.CrossRefGoogle Scholar
Brew, B. J., Rosenblum, M., Cronin, K., and Price, R. W. (1995). “AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations,” Ann. Neurol. 38(4): 563–70.CrossRefGoogle ScholarPubMed
Brito, M. O. and Doyle, T. (2007). “Movement and extrapyramidal disorders associated with interferon use in HIV/hepatitis C coinfection,” AIDS 21(14): 1987–9.CrossRefGoogle ScholarPubMed
De Mattos, J. P., Rosso, A. L., Carneiro, A. J., and Novis, S. (1993). “Spinal myoclonus: report of four cases,” Arq. Neuropsiquiatr. 51(4): 498–501.CrossRefGoogle ScholarPubMed
de Toffol, B., Vidailhet, M., Gray, F., Besnier, J. M., Menage, P., Lescs, M. C., et al. (1994). “Isolated motor control dysfunction related to progressive multifocal leukoencephalopathy during AIDS with normal MRI,” Neurology 44(12): 2352–5.CrossRefGoogle ScholarPubMed
Factor, S. A., Troche-Panetto, M., and Weaver, S. A. (2003) “Dystonia in AIDS: report of four cases,” Mov. Disord. 18(12): 1492–8.CrossRefGoogle ScholarPubMed
Gago, M. F., Rosas, M. J., Linhares, P., Massano, J., Sarmento, A., and Vaz, R. (2011). “Deep brain stimulation of the subthalamic nucleus for Parkinson’s disease in a patient with HIV infection: dual clinical benefit,” Case Rep. Neurol. 3(3): 219–22.CrossRefGoogle Scholar
Gaig, C., Munoz, E., Valls-Sole, J., Marti, M. J., and Tolosa, E. (2007). “Eating-induced facial myoclonic dystonia probably due to a putaminal lesion,” Mov. Disord. 22(6): 877–80.CrossRefGoogle ScholarPubMed
Happe, S., Kundmuller, L., Reichelt, D., Husstedt, I. W., and Evers, S. (2007). “Comorbidity of restless legs syndrome and HIV infection,” J. Neurol. 254(10): 1401–6.CrossRefGoogle ScholarPubMed
Heaton, R. K., Clifford, D. B., Franklin, D. R., Jr., Woods, S. P., Ake, C., Vaida, F., et al. (2010). “HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study,” Neurology 75(23): 2087–96.CrossRefGoogle ScholarPubMed
Hersh, B. P., Rajendran, P. R., and Battinelli, D. (2001). “Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART,” Neurology 56(2): 278–9.CrossRefGoogle ScholarPubMed
Hettige, S., Samuel, M., Clough, C., Hulse, N., and Ashkan, K. (2009). “Deep brain stimulation for Parkinson’s disease when HIV coexists,” Mov. Disord. 24(14): 2169–71.CrossRefGoogle ScholarPubMed
Hriso, E., Kuhn, T., Masdeu, J. C., and Grundman, M. (1991). “Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy,” Am. J. Psychiatry 148(11): 1558–61.Google ScholarPubMed
Itoh, K., Mehraein, P., and Weis, S. (2000). “Neuronal damage of the substantia nigra in HIV-1 infected brains,” Acta Neuropathol. 99(4): 376–84.CrossRefGoogle ScholarPubMed
Jang, W., Kim, J. S., Ahn, J. Y., and Kim, H. T. (2011). “Reversible progressive supranuclear palsy-like phenotype as an initial manifestation of HIV infection,” Neurol. Sci. 35(5): 1169–71.Google Scholar
Jankovic, J. (1986). “Whipple’s disease of the central nervous system in AIDS,” N. Engl. J. Med. 315(16): 1029–30.Google Scholar
Jankovic, J. (2009). “Treatment of hyperkinetic movement disorders,” Lancet Neurol. 8(9): 844–56.CrossRefGoogle ScholarPubMed
Jankovic, J. and Clarence-Smith, K. (2011). “Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders,” Expert Rev. Neurother. 11(11): 1509–23.CrossRefGoogle ScholarPubMed
Kobylecki, C., Silverdale, M. A., Varma, A., Dick, J. P., and Kellett, M. W. (2009). “HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy,” Mov. Disord. 24(16): 2441–2.Google ScholarPubMed
Koppel, B. S. and Daras, M. (1992). “Segmental myoclonus preceding herpes zoster radiculitis,” Eur. Neurol. 32(5): 264–6.CrossRefGoogle ScholarPubMed
Lee, M. S. and Marsden, C. D. (1994). “Movement disorders following lesions of the thalamus or subthalamic region,” Mov. Disord. 9(5): 493–507.CrossRefGoogle ScholarPubMed
Lekoubou, A., Njouoguep, R., Kuate, C., and Kengne, A. P. (2010). “Cerebral toxoplasmosis in Acquired Immunodeficiency Syndrome (AIDS) patients also provides unifying pathophysiologic hypotheses for Holmes tremor,” BMC Neurol. 10: 37.Google Scholar
Maggi, P., de Mari, M., De Blasi, R., Armenise, S., Romanelli, C., Andreula, C., et al. (1996). “Choreoathetosis in acquired immune deficiency syndrome patients with cerebral toxoplasmosis,” Mov. Disord. 11(4): 434–6.CrossRefGoogle ScholarPubMed
Manji, H., Sweeney, B., Connolly, S., Hughes, A., Miller, R. F., and Harrison, M. J. (1995). “Movement disorders in AIDS: infective, neoplastic and iatrogenic causes,” Parkinsonism Relat. Disord. 1(1): 13–19.CrossRefGoogle ScholarPubMed
Mattos, J. P., Rosso, A. L., Correa, R. B., and Novis, S. A. (2002). “Movement disorders in 28 HIV-infected patients,” Arq. Neuropsiquiatr. 60(3-A): 525–30.CrossRefGoogle ScholarPubMed
McArthur, J. C. (2004). “HIV dementia: an evolving disease,” J. Neuroimmunol. 157(1–2): 3–10.CrossRefGoogle Scholar
McArthur, J. C., Brew, B. J., and Nath, A. (2005). “Neurological complications of HIV infection,” Lancet Neurol. 4(9): 543–55.CrossRefGoogle ScholarPubMed
Mirsattari, S. M., Power, C., and Nath, A. (1998). “Parkinsonism with HIV infection,” Mov. Disord. 13(4): 684–9.CrossRefGoogle ScholarPubMed
Nath, A., Hobson, D. E., and Russell, A. (1993). “Movement disorders with cerebral toxoplasmosis and AIDS,” Mov. Disord. 8(1): 107–12.CrossRefGoogle ScholarPubMed
Nath, A., Jankovic, J., and Pettigrew, L. C. (1987). “Movement disorders and AIDS,” Neurology 37(1): 37–41.CrossRefGoogle ScholarPubMed
Navia, B. A., Jordan, B. D., and Price, R. W. (1986). “The AIDS dementia complex: I. Clinical features,” Ann. Neurol. 19(6): 517–24.CrossRefGoogle ScholarPubMed
Pandey, K., Sinha, P. K., Rabidas, V., Kumar, N., Bimal, S., Verma, N., et al. (2008). “HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: a case report,” Cases J. 1(1): 183.CrossRefGoogle ScholarPubMed
Pezzini, A., Zavarise, P., Palvarini, L., Viale, P., Oladeji, O., and Padovani, A. (2002). “Holmes’ tremor following midbrain Toxoplasma abscess: clinical features and treatment of a case,” Parkinsonism Relat. Disord. 8(3): 177–80.CrossRefGoogle ScholarPubMed
Piccolo, I., Causarano, R., Sterzi, R., Sberna, M., Oreste, P. L., Moioli, C., Caggese, L., and Girotti, F. (1999). “Chorea in patients with AIDS,” Acta Neurol. Scand. 100(5): 332–6.CrossRefGoogle ScholarPubMed
Rabhi, S., Amrani, K., Maaroufi, M., Khammar, Z., Khibri, H., Ouazzani, M., et al. (2011). “Hemichorea-hemiballismus as an initial manifestation in a Moroccan patient with acquired immunodeficiency syndrome and toxoplasma infection: a case report and review of the literature,” Pan. Afr. Med. J. 10: 9.CrossRefGoogle Scholar
Rieder, C. R. and Ziomkowski, S. C. (2005). “Head tremor and progressive multifocal leukoencephalopathy in AIDS patients: report of two cases,” Arq. Neuropsiquiatr. 63(1): 150–3.CrossRefGoogle ScholarPubMed
Rosso, A. L., Mattos, J. P., Correa, R. B., Nicaretta, D. H., and Novis, S. A. (2009). “Parkinsonism and AIDS: a clinical comparative study before and after HAART,” Arq. Neuropsiquiatr. 67(3B): 827–30.CrossRefGoogle ScholarPubMed
Sacktor, N. C., Skolasky, R. L., Lyles, R. H., Esposito, D., Selnes, O. A., and McArthur, J. C. (2000). “Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors,” J. Neurovirol. 6(1): 84–8.CrossRefGoogle ScholarPubMed
Sanchez-Ramos, J. R., Factor, S. A., Weiner, W. J., and Marquez, J. (1989). “Hemichorea-hemiballismus associated with acquired immune deficiency syndrome and cerebral toxoplasmosis,” Mov. Disord. 4(3): 266–73.CrossRefGoogle ScholarPubMed
Scott, B. L. and Jankovic, J. (1996). “Delayed-onset progressive movement disorders after static brain lesions,” Neurology 46(1): 68–74.CrossRefGoogle ScholarPubMed
Scott, K. M., Parker, F., and Heckmann, J. M. (2009). “Opsoclonus-myoclonus syndrome and HIV-infection,” J. Neurol. Sci. 284(1–2): 192–5.CrossRefGoogle ScholarPubMed
Solomons, R., Slogrove, A., Schoeman, J., Marais, B., van Zyl, G., Maritz, J., and van Toorn, R. (2011). “Acute extrapyramidal dysfunction in two HIV-infected children,” J. Trop. Pediatr. 57(3): 227–31.CrossRefGoogle ScholarPubMed
Sporer, B., Seelos, K., Asmus, F., Boetzel, K., and Pfister, H. W. (2005). “Posterior fossa tremor induced by HIV-associated progressive multifocal leukoencephalopathy,” Eur. Neurol. 53(2): 96–7.CrossRefGoogle ScholarPubMed
Teive, H. A., Troiano, A. R., Cabral, N. L., Becker, N., and Werneck, L. C. (2000). “Hemichorea-hemiballism associated to cryptococcal granuloma in a patient with AIDS: case report,” Arq. Neuropsiquiatr. 58(3B): 965–8.CrossRefGoogle Scholar
Theodore, S., Cass, W. A., Nath, A., and Maragos, W. F. (2007). “Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration,” Curr. HIV Res. 5(3): 301–13.CrossRefGoogle ScholarPubMed
Tisch, S. and Brew, B. (2009). “Parkinsonism in HIV-infected patients on highly active antiretroviral therapy,” Neurology 73(5): 401–3.CrossRefGoogle ScholarPubMed
Wang, G. J., Chang, L., Volkow, N. D., Telang, F., Logan, J., Ernst, T., et al. (2004). “Decreased brain dopaminergic transporters in HIV-associated dementia patients,” Brain 127(Pt 11): 2452–8.CrossRefGoogle ScholarPubMed
Wiersinga, W. J., Prins, J. M., and van de Beek, D. (2012). “Therapy-resistant opsoclonus-myoclonus syndrome secondary to HIV-1 infection,” Clin. Infect. Dis. 54(3): 447–8.CrossRefGoogle ScholarPubMed
Zuniga, C., Lester, J., Diaz, S., Scorticati, M., and Micheli, F. (2005). “Persistent limb dystonia in a HIV positive patient with cerebral toxoplasmosis,” Journal of Neurological Sciences 22(4): 414–16.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×